- Overview
- Activity Format & Credit
- Register for Webinar
- Overview
-
More
- Activity Format & Credit
- Register for Webinar
STATEMENT OF NEED
Neuroendocrine tumors (NETs) are a heterogeneous group of rare tumors that originate from epithelial or nervous cells in the neuroendocrine system. They can arise from any organ, most commonly the gastrointestinal tract and lungs. Clinical presentation of NETs is highly variable, and patients can experience a broad spectrum of symptoms that significantly impact well-being and make diagnosis challenging. The last decade has seen progress in therapy for NETs based on improved pathological categorization and molecular understanding, resulting in increasing therapeutic choices. Therefore, it is crucial for clinicians to remain up to date on emerging diagnostic techniques and therapies to improve outcomes for their patients with NETs (Sultana et al, 2023). This live webinar, presented by Aman Chauhan, MD, Associate Professor of Medical Oncology, Leader of the Neuroendocrine Tumor Program, and Co-Director of the Theranostics Program at the University of Miami, Sylvester Comprehensive Cancer Center, will explore strategies for optimizing NET outcomes by closing the gaps in diagnosis and care.
TARGET AUDIENCE
Medical/radiation/surgical oncologists, pathologists, endocrinologists, gastroenterologists, advanced practice providers, and other healthcare professionals (HCPs) involved in the treatment of patients with neuroendocrine tumors (NETs).
LEARNING OBJECTIVES
- Recognize the diverse clinical presentations of NETs to enhance differential diagnosis skills
- Identify patients at high risk for recurrence based on disease-related factors and patient characteristics
- Develop guideline-concordant, personalized treatment plans for patients with NETs, incorporating insights from recent clinical trials of novel therapies
REGISTRATION
JOINTLY ACCREDITED PROVIDER
In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS
i3 Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.
Physician Assistants/Associates
July 17, 2025
i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until 7/17/25. PAs should only claim credit commensurate with the extent of their participation.
August 5, 2025
i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until 8/5/25. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioners
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health endorses the standards of the ACCME that require everyone in a position to control the content of a CME activity to disclose all financial relationships with ineligible companies that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and ineligible companies:
Aman Chauhan, MD, discloses that he has served on an advisory board or panel for Boehringer Ingelheim, Curium, Exelixis, Novartis, Sanofi, and Seneca Therapeutics.
The i3 Health planners, reviewers, and managers have nothing to disclose.
i3 Health has mitigated all relevant financial relationships.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.
TECHNOLOGY REQUIREMENTS FOR VIRTUAL CME | NCPD | CPE ACTIVITIES
For virtual (asynchronous, archived live, home study; synchronous webinars) CME/NCPD/CPE activities, include access to system requirements:
- The Internet browser(s) supported and minimum versions of each required by the learner to complete the online activity.
- The minimum memory, storage, processor, and Internet speeds require by the learner to complete the online activity.
UNAPPROVED USE DISCLOSURE
i3 Health requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
DISCLAIMER
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
COMMERCIAL SUPPORT
This educational activity is supported by a medical education grant from Exelixis, Inc.
Aggregate participant data will be shared with commercial supporters of this activity.
CONTACT INFORMATION
Technical queries or questions regarding activity credit should be directed to i3 Health at support@i3health.com.
FORMAT
Live Webinar
CREDIT
1.0 AMA PRA Category 1 Credit™
1.0 AAPA Category 1 CME credit
ESTIMATED TIME TO COMPLETE
60 minutes
DATES AVAILABLE
Explore the evolving landscape of neuroendocrine tumor (NET) care in our live webinar, with two available dates to register: July 17 at 12:00 PM ET and August 5 at 3:00 PM ET. NETs are a rare and diverse group of tumors that can arise throughout the neuroendocrine system, often presenting with a wide range of symptoms that make diagnosis and management complex. This webinar will highlight recent advances in understanding NETs, offering insights into improved diagnostic techniques and expanding therapeutic options.
Topics to be covered include:
- The varied clinical presentations of NETs, from asymptomatic to severe cases
- Approaches to differential diagnosis and the latest emerging diagnostic tools
- Breakthroughs in therapeutic strategies and treatment advances
- Best practices for developing personalized treatment plans
- Real-world patient case discussions to illustrate practical applications
- And more
Join us to gain valuable knowledge and actionable strategies for optimizing outcomes in NET care.
REGISTER NOW